StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
80
This month
1
This week
1
This year
5
Yesterday
1
Publishing Date
2023 - 11 - 29
2
2023 - 11 - 28
2
2023 - 11 - 09
1
2023 - 11 - 07
2
2023 - 11 - 06
1
2023 - 10 - 28
1
2023 - 10 - 27
1
2023 - 10 - 24
1
2023 - 10 - 04
1
2023 - 08 - 30
1
2023 - 08 - 03
3
2023 - 08 - 02
1
2023 - 07 - 27
1
2023 - 06 - 27
2
2023 - 06 - 05
1
2023 - 05 - 25
1
2023 - 05 - 24
1
2023 - 05 - 19
1
2023 - 05 - 11
1
2023 - 05 - 10
1
2023 - 05 - 09
1
2023 - 05 - 08
1
2023 - 04 - 27
1
2023 - 04 - 21
1
2023 - 03 - 28
1
2023 - 03 - 18
1
2023 - 02 - 09
1
2022 - 10 - 28
1
2022 - 09 - 10
1
2022 - 08 - 15
1
2022 - 07 - 29
1
2022 - 06 - 11
1
2022 - 06 - 01
1
2022 - 05 - 27
2
2022 - 05 - 03
1
2022 - 04 - 29
1
2022 - 04 - 05
1
2022 - 03 - 10
1
2022 - 02 - 17
1
2022 - 02 - 02
1
2021 - 12 - 13
2
2021 - 11 - 19
1
2021 - 11 - 10
1
2021 - 11 - 04
2
2021 - 10 - 29
2
2021 - 10 - 05
1
2021 - 09 - 17
2
2021 - 09 - 16
2
2021 - 09 - 15
2
2021 - 09 - 14
2
2021 - 09 - 09
1
2021 - 08 - 19
1
2021 - 08 - 18
2
2021 - 08 - 11
1
2021 - 07 - 30
1
2021 - 05 - 24
1
2021 - 05 - 06
1
2021 - 05 - 05
1
2021 - 04 - 30
1
2021 - 02 - 03
1
Sector
Commercial services
2
Communications
1
Electronic technology
1
Energy minerals
1
Finance
1
Health technology
80
Industrial services
1
N/a
5
Utilities
1
Tags
Abbvie
77
Active
14
Aesthetic
22
Alliances
19
America
42
Antibody
17
Application
15
Approval
37
Atopic dermatitis
10
Biomidwest
43
Biotech-beach
10
Business
12
Cancer
53
Cd20
13
Chmp
10
Clinical-trials-phase-iii
26
Collaboration
23
Conference
32
Contract
13
Deadline
11
Dermatitis
14
Disease
65
Drug
75
Duobody
13
Earnings
22
Europe
16
Events
24
Expected
18
Eye
17
Fda
42
Financial
26
Financial results
12
Genetown
11
Global
113
Growing
24
Growth
174
Health
20
Leukemia
16
Market
383
Meeting
12
Migraine
23
N/a
783
Pharma
17
Pharmaceuticals
11
Phase 3
30
Positive
31
Reach
16
Report
97
Research
81
Results
80
Rinvoq
28
Risankizumab
14
Set
15
Skyrizi
16
Therapeutics
88
Therapy
40
Treatment
117
Trial
32
Ulcerative colitis
14
Year
12
Entities
Abbvie inc.
80
Alnylam pharmaceuticals, inc.
1
Alvotech lux holdings s.a.s.
5
Amgen inc.
3
Assembly biosciences, inc.
2
At&t inc.
1
Beam therapeutics inc.
1
Beigene, ltd.
1
Biogen inc.
1
Biohaven pharmaceutical holding company ltd.
1
Biontech se
4
Blueprint medicines corporation
1
Broadcom inc.
1
Canadian imperial bank of commerce
1
Canadian natural resources limited
1
Coherus biosciences, inc.
16
Collplant biotechnologies ltd.
1
Enbridge inc
1
Exicure, inc.
2
Genmab a/s
8
I-mab
2
Incyte corporation
1
Infinity pharmaceuticals, inc.
1
Ironwood pharmaceuticals, inc.
4
Johnson & johnson
10
Kamada ltd.
5
Karuna therapeutics, inc.
1
Mei pharma, inc.
1
Mirati therapeutics, inc.
1
Novartis ag
6
Novocure limited
1
Opko health, inc.
1
Pfizer, inc.
1
Pulse biosciences, inc
1
Reata pharmaceuticals, inc.
1
Regeneron pharmaceuticals, inc.
1
Royal bank of canada
1
Sangamo therapeutics, inc.
1
Seagen inc.
3
Sight sciences inc
1
Summit therapeutics inc.
2
Sun life financial inc.
1
Surface oncology, inc.
2
Teva pharmaceutical industries ltd
5
Tracon pharmaceuticals, inc.
1
Transalta corporation
1
Zai lab limited
1
Symbols
ABBV
80
AEM
39
ALNY
79
AMGN
53
APO
41
ARVL
178
AUY
39
BAM
52
BGNE
50
BIDU
39
BMY
64
BNPQF
73
BNPQY
73
BNTX
51
CHRS
45
CYTK
41
DAO
46
DRTT
38
FBIO
60
FNCTF
330
FRBA
87
GILD
51
GOLD
48
INCY
72
IONS
42
JD
40
JKS
38
JNJ
218
LGND
44
LLY
203
LTUM
59
LXRX
40
MDWD
48
MPC
53
MPLX
53
MS
205
NEE
43
NEP
42
NTES
57
NVS
52
NVSEF
38
PAYD
167
PFE
62
PGR
38
PPRUF
77
PPRUY
77
PRVB
41
REGN
84
SGEN
38
SNY
366
SNYNF
291
SRE
40
TAK
58
TEVJF
47
TK
48
TNK
47
TTOO
42
UAN
42
XNCR
39
XYF
94
Exchanges
Nasdaq
47
Nyse
80
Crawled Date
2023 - 11 - 29
2
2023 - 11 - 28
2
2023 - 11 - 07
2
2023 - 11 - 06
1
2023 - 10 - 28
1
2023 - 10 - 27
1
2023 - 10 - 24
1
2023 - 10 - 04
1
2023 - 08 - 30
1
2023 - 08 - 03
3
2023 - 08 - 02
1
2023 - 07 - 27
1
2023 - 06 - 27
2
2023 - 06 - 05
1
2023 - 05 - 25
1
2023 - 05 - 24
1
2023 - 05 - 19
1
2023 - 05 - 11
1
2023 - 05 - 10
1
2023 - 05 - 09
1
2023 - 05 - 08
1
2023 - 04 - 27
1
2023 - 04 - 21
1
2023 - 03 - 28
1
2023 - 03 - 18
1
2023 - 02 - 09
1
2022 - 10 - 28
1
2022 - 09 - 10
1
2022 - 08 - 15
1
2022 - 07 - 29
1
2022 - 06 - 11
1
2022 - 06 - 01
1
2022 - 05 - 27
2
2022 - 05 - 03
1
2022 - 04 - 29
1
2022 - 04 - 05
1
2022 - 03 - 12
1
2022 - 02 - 17
1
2022 - 02 - 02
1
2021 - 12 - 13
2
2021 - 11 - 19
1
2021 - 11 - 10
1
2021 - 11 - 05
1
2021 - 11 - 04
1
2021 - 10 - 29
2
2021 - 10 - 05
1
2021 - 09 - 17
2
2021 - 09 - 16
2
2021 - 09 - 15
2
2021 - 09 - 14
2
2021 - 09 - 09
1
2021 - 08 - 19
1
2021 - 08 - 18
2
2021 - 08 - 11
1
2021 - 07 - 30
1
2021 - 05 - 24
1
2021 - 05 - 06
1
2021 - 05 - 05
1
2021 - 04 - 30
1
2021 - 02 - 03
1
Crawled Time
01:00
1
02:00
3
05:00
1
07:00
1
08:00
2
08:20
1
09:00
1
12:00
9
12:20
1
12:30
1
13:00
7
13:07
1
13:15
2
13:30
1
14:00
3
14:20
1
14:30
1
15:00
5
15:15
2
16:00
4
16:20
3
17:00
3
18:00
1
19:00
1
20:00
7
21:00
7
22:00
3
23:00
7
Source
investor.assemblybio.com
2
www.biospace.com
29
www.globenewswire.com
27
www.prnewswire.com
22
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Results
symbols :
Abbv
save search
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published:
2024-04-18
(Crawled : 19:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
1.52%
|
O:
0.75%
H:
0.0%
C:
0.0%
rinvoq
positive
cell
results
study
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Published:
2024-03-20
(Crawled : 20:00)
- globenewswire.com
ALVO
|
News
|
$13.23
2.64%
2.57%
1.7M
|
n/a
|
-13.2%
|
O:
-1.58%
H:
1.87%
C:
0.53%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-4.93%
|
O:
-0.03%
H:
0.0%
C:
0.0%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-6.62%
|
O:
-0.89%
H:
0.0%
C:
0.0%
KMDA
|
News
|
$5.05
-0.98%
-0.99%
27K
|
Health Technology
|
-11.58%
|
O:
0.68%
H:
0.0%
C:
-1.86%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
|
-1.51%
|
O:
0.58%
H:
1.2%
C:
0.84%
business
year
update
financial
results
I-Mab Reports Full Year 2023 Financial Results and Business Update
Published:
2024-03-14
(Crawled : 21:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-7.71%
|
O:
-0.07%
H:
0.0%
C:
0.0%
TCON
|
$1.97
-6.64%
-7.11%
240K
|
Health Technology
|
347.9%
|
O:
-6.31%
H:
4.85%
C:
-8.54%
IMAB
|
$1.81
0.56%
0.55%
340K
|
Health Technology
|
0.0%
|
O:
-5.56%
H:
9.41%
C:
9.41%
business
year
update
financial
results
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Published:
2024-02-02
(Crawled : 14:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
1.71%
|
O:
3.59%
H:
0.0%
C:
0.0%
abbvie
financial
results
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Published:
2024-01-08
(Crawled : 13:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
3.03%
|
O:
0.52%
H:
0.0%
C:
0.0%
positive
program
trial
results
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Published:
2023-11-29
(Crawled : 14:30)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
19.69%
|
O:
-0.73%
H:
0.78%
C:
0.35%
lung
abbvie
positive
cancer
cell
topline
trial
results
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
Published:
2023-11-29
(Crawled : 12:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
19.69%
|
O:
-0.73%
H:
0.78%
C:
0.35%
CLGN
|
$5.22
-2.54%
1.2K
|
Health Technology
|
-9.25%
|
O:
-3.32%
H:
4.15%
C:
-3.43%
biotechnologies
financial
results
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
Published:
2023-11-28
(Crawled : 21:00)
- globenewswire.com
ALVO
|
News
|
$13.23
2.64%
2.57%
1.7M
|
n/a
|
34.9%
|
O:
1.02%
H:
0.0%
C:
-5.05%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-2.72%
|
O:
0.18%
H:
0.12%
C:
-0.16%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-2.31%
|
O:
-0.04%
H:
0.0%
C:
0.0%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
19.69%
|
O:
-0.73%
H:
0.78%
C:
0.35%
KMDA
|
News
|
$5.05
-0.98%
-0.99%
27K
|
Health Technology
|
8.46%
|
O:
0.73%
H:
0.0%
C:
-1.04%
business
update
financial
results
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
Published:
2023-11-28
(Crawled : 21:00)
- globenewswire.com
ALVO
|
News
|
$13.23
2.64%
2.57%
1.7M
|
n/a
|
34.9%
|
O:
1.02%
H:
0.0%
C:
-5.05%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-2.31%
|
O:
-0.04%
H:
0.0%
C:
0.0%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
19.69%
|
O:
-0.73%
H:
0.78%
C:
0.35%
KMDA
|
News
|
$5.05
-0.98%
-0.99%
27K
|
Health Technology
|
8.46%
|
O:
0.73%
H:
0.0%
C:
-1.04%
business
update
financial
results
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
Published:
2023-11-09
(Crawled : 13:30)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
15.88%
|
O:
-1.81%
H:
0.43%
C:
-2.1%
IRWD
|
$7.94
4.47%
4.28%
2.5M
|
Health Technology
|
-14.19%
|
O:
2.93%
H:
4.37%
C:
0.21%
pharmaceuticals
ironwood
results
Genmab Announces Financial Results for the First Nine Months of 2023
Published:
2023-11-07
(Crawled : 16:00)
- globenewswire.com
GNMSF
|
$290.38
3.83%
220
|
Health Technology
|
-0.26%
|
O:
0.39%
H:
4.92%
C:
1.52%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
0.97%
|
O:
0.24%
H:
0.18%
C:
0.16%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-2.48%
|
O:
0.18%
H:
0.0%
C:
0.0%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
17.36%
|
O:
-0.28%
H:
0.0%
C:
0.0%
GMAB
|
$28.72
1.38%
1.36%
360K
|
Health Technology
|
-0.52%
|
O:
0.24%
H:
3.44%
C:
2.07%
BNTX
|
$86.82
0.75%
0.75%
1.6M
|
Health Technology
|
-12.94%
|
O:
-0.35%
H:
3.09%
C:
3.03%
financial
results
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published:
2023-11-07
(Crawled : 15:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
17.36%
|
O:
-0.28%
H:
0.0%
C:
0.0%
SMMT
A
|
$3.51
0.0%
1.7M
|
Health Technology
|
60.55%
|
O:
-0.46%
H:
6.68%
C:
-11.75%
PLSE
|
$7.2
-2.17%
-2.22%
180K
|
Health Technology
|
38.54%
|
O:
0.39%
H:
6.43%
C:
1.92%
BIIB
|
$194.39
2.03%
1.99%
1.6M
|
Health Technology
|
-21.82%
|
O:
-0.82%
H:
0.73%
C:
-0.4%
ALNY
|
$144.315
-0.58%
-0.59%
700K
|
Health Technology
|
-13.6%
|
O:
1.06%
H:
2.42%
C:
0.76%
therapeutics
financial
results
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
Published:
2023-11-06
(Crawled : 21:00)
- globenewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
17.36%
|
O:
-0.28%
H:
0.0%
C:
0.0%
CHRS
|
$2.06
3.0%
2.91%
2.9M
|
Health Technology
|
-41.53%
|
O:
-22.6%
H:
3.28%
C:
-9.85%
business
financial
results
Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024
Published:
2023-10-28
(Crawled : 12:20)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
Email alert
Add to watchlist
fy2024
pharma
results
AbbVie Reports Third-Quarter 2023 Financial Results
Published:
2023-10-27
(Crawled : 20:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
15.11%
|
O:
-4.81%
H:
0.0%
C:
0.0%
abbvie
financial
results
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Published:
2023-10-24
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
14.98%
|
O:
0.3%
H:
0.0%
C:
0.0%
positive
treatment
topline
results
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
Published:
2023-10-04
(Crawled : 15:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
12.58%
|
O:
-0.89%
H:
0.0%
C:
0.0%
cls-484
cancer
preclinical
immunotherapy
potential
results
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
Published:
2023-08-30
(Crawled : 20:00)
- globenewswire.com
ALVO
|
News
|
$13.23
2.64%
2.57%
1.7M
|
n/a
|
35.87%
|
O:
0.21%
H:
3.28%
C:
1.54%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-10.68%
|
O:
-1.35%
H:
0.12%
C:
-1.03%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
12.29%
|
O:
0.16%
H:
0.0%
C:
0.0%
KMDA
|
News
|
$5.05
-0.98%
-0.99%
27K
|
Health Technology
|
-7.82%
|
O:
1.24%
H:
1.23%
C:
0.88%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
|
4.28%
|
O:
0.13%
H:
0.3%
C:
-0.73%
six
business
update
financial
results
Piramal Pharma Limited Announces Consolidated Results for Q1FY24
Published:
2023-08-03
(Crawled : 23:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
11.65%
|
O:
-0.05%
H:
1.07%
C:
-0.83%
fy24
pharma
results
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
Published:
2023-08-03
(Crawled : 20:00)
- globenewswire.com
SGHT
|
$5.14
-1.91%
-1.95%
130K
|
|
-36.19%
|
O:
0.62%
H:
10.26%
C:
6.92%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
11.65%
|
O:
-0.05%
H:
1.07%
C:
-0.83%
year
sciences
financial
results
← Previous
1
2
3
4
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.